Price Chart
Insider Transactions
| Date | Insider | Dir. | Shares | Value |
|---|---|---|---|---|
| Jun 26, 2026 | Lazzarato, David Angelo | Sell | 40,621 | — |
| Jun 26, 2026 | Lazzarato, David Angelo | Buy | 40,621 | — |
| Jun 26, 2026 | Lazzarato, David Angelo | Buy | 22,674 | $21K |
| Jun 26, 2026 | Yanofsky, Terry | Sell | 27,081 | — |
| Jun 26, 2026 | Yanofsky, Terry | Buy | 27,081 | — |
| Jun 26, 2026 | Yanofsky, Terry | Buy | 15,054 | $14K |
| Jun 26, 2026 | Bayern, Joseph | Sell | 27,081 | — |
| Jun 26, 2026 | Bayern, Joseph | Buy | 27,081 | — |
| Jun 26, 2026 | Bayern, Joseph | Buy | 3,197 | $3K |
| Jun 26, 2026 | Atkins, Margaret Shan | Sell | 27,081 | — |
| Jun 26, 2026 | Atkins, Margaret Shan | Buy | 27,081 | — |
| Jun 26, 2026 | Atkins, Margaret Shan | Buy | 3,197 | $3K |
| Jun 17, 2026 | Mongeau, Luc | Sell | 242,404 | — |
| Jun 17, 2026 | Mongeau, Luc | Buy | 242,404 | — |
| Jun 17, 2026 | Mongeau, Luc | Buy | 135,231 | $132K |
| Jun 17, 2026 | Mongeau, Luc | Buy | 1,056,152 | — |
| Jun 17, 2026 | Mongeau, Luc | Buy | 1,291,139 | — |
| Jun 17, 2026 | Stewart, Thomas Carlton | Sell | 21,966 | — |
| Jun 17, 2026 | Stewart, Thomas Carlton | Buy | 21,966 | — |
| Jun 17, 2026 | Stewart, Thomas Carlton | Buy | 9,285 | $9K |
| Jun 17, 2026 | Stewart, Thomas Carlton | Buy | 379,018 | — |
| Jun 17, 2026 | Stewart, Thomas Carlton | Buy | 463,347 | — |
| Jun 17, 2026 | Gedeon, Christelle | Sell | 105,747 | — |
| Jun 17, 2026 | Gedeon, Christelle | Buy | 105,747 | — |
| Jun 17, 2026 | Gedeon, Christelle | Buy | 58,994 | $57K |
| Jun 17, 2026 | Gedeon, Christelle | Buy | 396,012 | — |
| Jun 17, 2026 | Gedeon, Christelle | Buy | 484,122 | — |
Score uses open-market buys only
· 7 open-market
· 13 plan / compensation shown but not scored
· Return is unrealized, to today's price; a
“· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
| Component | Points | Max |
|---|---|---|
| Conviction (unique buyers) ✓ FREE PREVIEW | 15 | 30 |
| Buy/sell ratio | 20 | |
| Dollar value | 25 | |
| Lobbying activity | 15 | |
| Contract wins | 10 | |
| Insider track record | 10 | |
| Private placements | 8 | |
| Confluence bonus | 10 | |
| Cluster timing (velocity) | 10 | |
| Buy/sell reversal pattern | 8 | |
| Total | 0 | 100 |
Buying Insiders
| Insider | Credibility | Buy Value (90d) |
|---|---|---|
| Mongeau, Luc | — | $132K |
| Gedeon, Christelle | — | $57K |
| Lazzarato, David Angelo | — | $21K |
| Yanofsky, Terry | — | $14K |
| Stewart, Thomas Carlton | — | $9K |
| Atkins, Margaret Shan | — | $3K |
| Bayern, Joseph | — | $3K |
Credibility score: historical hit rate × avg 90d return × sample size.
View full insider leaderboard →
Lobbying Registrations
No active OCL lobbying registrations in the last 90 days.
Analyst plan →
Government Contract Wins
No government contract wins in the last 90 days.
Analyst plan →
Private Placements
Private placement history, deal size, and lock-up expiry tracking.
Analyst plan →
Indigenous Consultation
No Indigenous consultation records on file for WEED.
SEDAR+ Filings
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes.
Search SEDAR+ →
Short Interest
Shares short
16,514,132
Net change
-140,301
(-0.8%)
History
Jun 30:
16,514,132
Jun 15:
16,654,433
May 31:
15,047,632
May 15:
17,331,110
Apr 30:
17,909,558
Apr 15:
15,308,982
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Wikipedia Attention
Views (30d)
1,617
Daily English-Wikipedia pageviews (Wikimedia). Traffic spikes often coincide with news — a
public-attention indicator, not investment advice.
Clinical Trials
| Phase | Status | Trial |
|---|---|---|
| P1/P2 | Completed | A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and |
| P2 | Completed | The Effects of CBD Isolate on Menstrual-Related Symptoms |
| P1 | Completed | Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of |
| P2 | Completed | Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Su |
| P2 | Completed | A Randomized Controlled Test of the Effects of CHI-554 on Fear. |
| P1 | Terminated | CBD in Postmenopausal Women With Osteopenia |
| — | Unknown | Canadian Registry for the Use of Spectrum Therapeutics Cannabis Produc |
| P2 | Terminated | CHI-907 CBD Extract and Experiences of Test Anxiety |
| P2 | Terminated | Investigation of the Efficacy and Safety of CHI-921 in Insomnia. |
| P2 | Withdrawn | CHI-902 for Treatment of Social Anxiety Disorder |
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and
terminations are material catalysts for clinical-stage companies — not investment advice.
Boardroom Connections
| Insider | Other boards | Also an insider at |
|---|---|---|
| Atkins, Margaret Shan | 1 | ACB (10) |
People who file as insiders here and at other TSX/TSXV companies (number in brackets = that company's
Confluence Score). A well-connected insider taking a seat at a new junior can be an early tell. Matched by
name across SEDI filings; funds and 10%+ holders excluded.